PEB Attracts US Investment and Undertakes Share Placement

30 July 2018
Company Announcement

PACIFIC EDGE ATTRACTS US INVESTMENT AND UNDERTAKES SHARE PLACEMENT

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has accepted an investment offer of NZ$ 2.622
million from Manchester Management Company, LLC (MMC), a US privately owned fund specialising in
biotech and life sciences investments.

Pacific Edge will issue 8,195,338 shares (in aggregate) to MMC at NZ$0.32 cents per ordinary share, being a
24.75% premium over the VWAP for the 5 day trading period prior to 27 July 2018.

Pacific Edge Chairman, Chris Gallaher, commented: "The US fund adds further depth to the Company’s
register and is a reflection of the growing international investor interest in Pacific Edge.

“Our ability to attract new investment from specialist investors is testament to our innovative product offer,
the traction we are gaining in our commercial journey in the USA and the potential Pacific Edge has to gain a
strong share of the multi-billion dollar bladder cancer diagnostics market.”

Manchester Management Managing Member, James Besser, said: "Manchester is excited with this
investment in Pacific Edge, gaining direct exposure to a vertically integrated, cancer diagnostic company with
an established commercial presence, clinically validated products and a strong management team.”

Manchester also has investments in emerging medical technology companies including Modular Medical,
and Fennec Pharmaceuticals.

The additional capital further strengthens Pacific Edge’s balance sheet and will provide added support as
Pacific Edge continues to grow sales for its Cxbladder bladder cancer diagnostics technology and deliver
strengthening financial results. Pacific Edge remains focused on achieving a positive net cashflow position.

Pacific Edge owns world leading molecular diagnostics tests for the detection and management of urothelial
cancer (including bladder cancer). It is seeking to disrupt decades of established medical practice and has
been gaining traction in the US healthcare market, demonstrated by a number of significant achievements,
including:

• An established commercial presence in the USA, with a CLIA accredited laboratory and experienced
US sales force;
• Expanding presence and adoption by urologists;
• Agreed cover and contract pricing with the Veterans Administration and TRICARE;
• Currently in commercial negotiations with healthcare provider Kaiser Permanente, following
successful completion of a large scale User Programme;
• Significantly progressed in submissions to be included in Local Coverage Determination (LCD) which
will allow for reimbursement of CMS patients;
• Issued CPT Codes by the American Medical Association, a key factor in the reimbursement process
in the USA; and
• Ongoing clinical validation which demonstrates the outperformance of Cxbladder compared to other
commonly used diagnostics.

Adoption of Pacific Edge’s Cxbladder tests is growing and, for the year ended 31 March 2018, the Company
delivered a 28% increase in laboratory throughput (with 82% of throughput being billable) and grew cash

30 July 2018
Company Announcement

revenue by 6%. In addition to the $16.2 million cash on hand at FY18 year end, the new investment provides
additional support for Pacific Edge to drive its commercial growth.

Pacific Edge is the only company in the world to have a suite of molecular diagnostic tests in bladder cancer
that addresses different needs throughout the diagnostic and treatment pathway - from investigation of
haematuria through to the management of patients who have the disease and are coming back to the clinic
for evaluation of the recurrence of bladder cancer. Pacific Edge is focused on positioning its highly accurate,
non-invasive and cost effective Cxbladder technology as the preferred diagnostic tool for clinicians and
urologists, and is seeing increasing demand and uptake from both private and public healthcare providers.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery
and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder
suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and
management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder
cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s
products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who
have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of
a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence
of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer
has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients
with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of
recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer.
Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other
Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability
of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be
warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.